Analysts are more negative on FibroGen post-earnings, cuttin...
Analysts are more negative on FibroGen post-earnings, cutting revenue estimates and predicting higher losses. Despite projected revenue growth, FibroGen's expected growth is slower than the industry. The consensus price target dropped significantly, showing analysts' lack of confidence in the latest results and a lower future valuation estimate for FibroGen.
Analysts Have Been Trimming Their FibroGen, Inc. (NASDAQ:FGEN) Price Target After Its Latest Report
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment